Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: Biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide dna microarray

Arthritis and Rheumatology

Volumn 66, Issue 6, 2014, Pages 1421-1431

  Sanayama, Yoshie ^a,b   Ikeda, Kei ^a,b   Saito, Yukari ^a,b   Kagami, Shin Ichiro ^b   Yamagata, Mieko ^b   Furuta, Shunsuke ^b   Kashiwakuma, Daisuke ^b   Iwamoto, Itsuo ^b   Umibe, Takeshi ^c   Nawata, Yasushi ^d   Matsumura, Ryutaro ^e   Sugiyama, Takao ^f   Sueishi, Makoto ^f   Hiraguri, Masaki ^g   Nonaka, Ken ^h   Ohara, Osamu ^h   Nakajima, Hiroshi ^a,b  

^a CHIBA UNIVERSITY HOSPITAL   (Japan)

^b ASAHI GENERAL HOSPITAL   (Japan)

^c Matsudo City Hospital   (Japan)

^d Chibaken Saiseikai Narashino Hospital   (Japan)

^e SAKURA NATIONAL HOSPITAL   (Japan)

^f SHIMOSHIZU HOSPITAL   (Japan)

^g NARITA RED CROSS HOSPITAL   (Japan)

^h KAZUSA DNA RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TOCILIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IFI6 GENE; MALE; MT1G GENE; MX2 GENE; OASL GENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE I; LEUKOCYTES, MONONUCLEAR; MALE; METALLOTHIONEIN; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84901611446     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38400     Document Type: Article

References (53)

1. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK,. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 864-72.
2. Scott DL, Wolfe F, Huizinga TW,. Rheumatoid arthritis. Lancet 2010; 376: 1094-108.
3. Feldmann M, Maini RN,. Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163-96.
4. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P,. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861-74.
5. McInnes IB, Schett G,. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19.
6. Ikeda K, Cox S, Emery P,. Aspects of early arthritis. Biological therapy in early arthritis-overtreatment or the way to go? Arthritis Res Ther 2007; 9: 211.
7. Pavy S, Toonen EJ, Miceli-Richard C, Barrera P, van Riel PL, Criswell LA, et al. Tumour necrosis factor α -308G→A polymorphism is not associated with response to TNFα blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis 2010; 69: 1022-8.
8. Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 69-74.
9. Lequerre T, Gauthier-Jauneau AC, Bansard C, Derambure C, Hiron M, Vittecoq O, et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 2006; 8: R105.
10. Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, et al. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-α monoclonal antibody, infliximab. Rheumatology (Oxford) 2008; 47: 780-8.
11. Tanino M, Matoba R, Nakamura S, Kameda H, Amano K, Okayama T, et al. Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells. Biochem Biophys Res Commun 2009; 387: 261-5.
12. Lindberg J, Wijbrandts CA, van Baarsen LG, Nader G, Klareskog L, Catrina A, et al. The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis. PLoS One 2010; 5: e11310.
13. Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 2012; 14: R95.
14. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of Active controlled Monotherapy Used for Rheumatoid Arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66: 1162-7.
15. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab in Combination with Traditional Disease-Modifying Antirheumatic Drug Therapy Study. Arthritis Rheum 2008; 58: 2968-80.
16. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013; 381: 1541-50.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
18. Fries JF, Spitz PW, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
19. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
20. Van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL,. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/ International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40.
21. Aletaha D, Smolen J,. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: S100-8.
22. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
23. Theofilopoulos AN, Baccala R, Beutler B, Kono DH,. Type I interferons (α/β) in immunity and autoimmunity. Annu Rev Immunol 2005; 23: 307-36.
24. Van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007; 66: 1008-14.
25. Mavragani CP, La DT, Stohl W, Crow MK,. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-β/α ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum 2010; 62: 392-401.
26. Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing DM, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum 2010; 62: 3607-14.
27. Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011; 70: 2029-36.
28. O'Hanlon TP, Rider LG, Gan L, Fannin R, Paules RS, Umbach DM, et al. Gene expression profiles from discordant monozygotic twins suggest that molecular pathways are shared among multiple systemic autoimmune diseases. Arthritis Res Ther 2011; 13: R69.
29. Vosslamber S, Raterman HG, van der Pouw Kraan TC, Schreurs MW, von Blomberg BM, Nurmohamed MT, et al. Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis 2011; 70: 1153-9.
30. Van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TC, Baeten DL, et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther 2010; 12: R11.
31. Hogan VE, Holweg CT, Choy DF, Kummerfeld SK, Hackney JA, Teng YK, et al. Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab. Ann Rheum Dis 2012; 71: 1888-94.
32. Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, et al. Inhibition of plasma IL-6 in addition to maintenance of an efficacious trough level of infliximab associated with clinical remission in patients with rheumatoid arthritis: analysis of the RISING Study. Ann Rheum Dis 2012; 71: 1583-5.
33. Wilson LE, Widman D, Dikman SH, Gorevic PD,. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum 2002; 32: 163-73.
34. La Mantia L, Capsoni F,. Psoriasis during interferon β treatment for multiple sclerosis. Neurol Sci 2010; 31: 337-9.
35. Palace J, Leite MI, Nairne A, Vincent A,. Interferon β treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010; 67: 1016-7.
36. Cacopardo B, Benanti F, Pinzone MR, Nunnari G,. Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature. BMC Res Notes 2013; 6: 437.
37. Axtell RC, Raman C,. Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev 2012; 248: 23-35.
38. Wahren-Herlenius M, Dorner T,. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013; 382: 819-31.
39. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, et al. T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010; 16: 406-12.
40. Korn T, Bettelli E, Oukka M, Kuchroo VK,. IL-17 and Th17 cells. Annu Rev Immunol 2009; 27: 485-517.
41. Saito Y, Kagami S, Sanayama Y, Ikeda K, Suto A, Kashiwakuma D, et al. AT-rich-interactive domain-containing protein 5A functions as a negative regulator of retinoic acid receptor-related orphan nuclear receptor γt-induced Th17 cell differentiation. Arthritis Rheumatol 2014; 66: 1185-94.
42. Mitani Y, Takaoka A, Kim SH, Kato Y, Yokochi T, Tanaka N, et al. Cross talk of the interferon-α/β signalling complex with gp130 for effective interleukin-6 signalling. Genes Cells 2001; 6: 631-40.
43. Karin M, Richards RI,. Human metallothionein genes-primary structure of the metallothionein-II gene and a related processed gene. Nature 1982; 299: 797-802.
44. Richards RI, Heguy A, Karin M,. Structural and functional analysis of the human metallothionein-IA gene: differential induction by metal ions and glucocorticoids. Cell 1984; 37: 263-72.
45. Coyle P, Philcox JC, Carey LC, Rofe AM,. Metallothionein: the multipurpose protein. Cell Mol Life Sci 2002; 59: 627-47.
46. Schroeder JJ, Cousins RJ,. Interleukin 6 regulates metallothionein gene expression and zinc metabolism in hepatocyte monolayer cultures. Proc Natl Acad Sci U S A 1990; 87: 3137-41.
47. Lee DK, Carrasco J, Hidalgo J, Andrews GK,. Identification of a signal transducer and activator of transcription (STAT) binding site in the mouse metallothionein-I promoter involved in interleukin-6-induced gene expression. Biochem J 1999; 337: 59-65.
48. Abdel-Mageed AB, Agrawal KC,. Activation of nuclear factor κB: potential role in metallothionein-mediated mitogenic response. Cancer Res 1998; 58: 2335-8.
49. Sakurai A, Hara S, Okano N, Kondo Y, Inoue J, Imura N,. Regulatory role of metallothionein in NF-κB activation. FEBS Lett 1999; 455: 55-8.
50. Mocchegiani E, Costarelli L, Giacconi R, Cipriano C, Muti E, Tesei S, et al. Nutrient-gene interaction in ageing and successful ageing: a single nutrient (zinc) and some target genes related to inflammatory/immune response. Mech Ageing Dev 2006; 127: 517-25.
51. Toonen EJ, Gilissen C, Franke B, Kievit W, Eijsbouts AM, den Broeder AA, et al. Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis. PLoS One 2012; 7: e33199.
52. Koczan D, Drynda S, Hecker M, Drynda A, Guthke R, Kekow J, et al. Molecular discrimination of responders and nonresponders to anti-TNFα therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther 2008; 10: R50.
53. Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, et al. Disease Activity Score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the Clinical Disease Activity Index. Mod Rheumatol 2011; 21: 365-9.